Metformin's Role in Hyperlactatemia and Lactic Acidosis in ICU Patients: A Systematic Review.

Mueller, Livia; Moser, Michel; Prazak, Josef; Fuster, Daniel G; Schefold, Joerg C; Zuercher, Patrick (2023). Metformin's Role in Hyperlactatemia and Lactic Acidosis in ICU Patients: A Systematic Review. Pharmacology, 108(3), pp. 213-223. Karger 10.1159/000528252

[img]
Preview
Text
document.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (355kB) | Preview

INTRODUCTION

Metformin-treated patients may experience severe hyperlactatemia or lactic acidosis (LA). LA often requires intensive-care-unit (ICU) treatment, and mortality rates are high. Here, we investigate the impact of renal dysfunction and renal replacement therapy (RRT) on the outcomes of critically ill patients with metformin-associated LA (MALA). Furthermore, we assessed associations between mortality and metformin dose, metformin plasma/serum concentrations, lactate level, and arterial pH. Finally, we investigated whether the recommended classification in MALA, metformin-unrelated LA, metformin-induced LA, and LA in metformin therapy appears useful in this regard.

METHODS

We performed a retrospective analysis based on a systematic PubMed search for publications on hyperlactatemia/LA in metformin-treated ICU patients from January 1995 to February 2020. Case-level data including demographics and clinical conditions were extracted, and logistic regression analyses were performed.

RESULTS

A total of 92 ICU patients were reported. Two of these patients had no comorbidities interfering with lactate metabolism. In the overall group, arterial pH, lactate levels, and metformin plasma/serum concentrations were similar in survivors versus non-survivors. Ingested daily metformin doses and plasma/serum creatinine levels were significantly higher in survivors versus non-survivors (p = 0.007 vs. p = 0.024, respectively). Higher plasma/serum creatinine levels, higher lactate levels, and lower arterial pH were all associated with patients receiving RRT (all p < 0.05). Overall mortality was 22% (20 out of 92 patients) and did not differ between the RRT and non-RRT groups.

CONCLUSION

Mortality is high in ICU patients with metformin-associated hyperlactatemia/LA. Unexpectedly, higher ingested metformin dose and plasma/serum creatinine were associated with a better outcome. Survival was similar in patients with or without need for RRT.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > Clinic of Intensive Care
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Nephrology and Hypertension

UniBE Contributor:

Moser, Michel, Prazak, Josef, Fuster, Daniel Guido, Schefold, Jörg Christian, Zürcher, Patrick

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1423-0313

Publisher:

Karger

Language:

English

Submitter:

Pubmed Import

Date Deposited:

23 Jan 2023 15:01

Last Modified:

27 May 2023 00:12

Publisher DOI:

10.1159/000528252

PubMed ID:

36652938

Uncontrolled Keywords:

Critically ill Hyperlactatemia Intensive care unit Lactic acidosis Metformin

BORIS DOI:

10.48350/177692

URI:

https://boris.unibe.ch/id/eprint/177692

Actions (login required)

Edit item Edit item
Provide Feedback